JVMAX | PYCGX | JVMAX / PYCGX | |
Total Expense Ratio | N/A | N/A | - |
Annual Report Gross Expense Ratio | N/A | N/A | - |
Fund Existence | 28 years | 27 years | - |
Gain YTD | 2.046 | 3.836 | 53% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 1000 | 5000000 | 0% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 22.5B | 730M | 3,082% |
Annual Yield % from dividends | 0.67 | 1.42 | 47% |
Returns for 1 year | -2.62 | 8.47 | -31% |
Returns for 3 years | 2.26 | 2.20 | 103% |
Returns for 5 years | 22.67 | 16.09 | 141% |
Returns for 10 years | 32.20 | 6.99 | 461% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
HERFX | 10.33 | -0.01 | -0.10% |
Hartford Emerging Markets Equity F | |||
RYBOX | 58.38 | -0.21 | -0.36% |
Rydex Biotechnology A | |||
EPLPX | 22.01 | -0.18 | -0.81% |
NYLI Epoch U.S. Equity Yield Class A | |||
CMLCX | 57.35 | -0.62 | -1.07% |
American Funds American Mutual 529C | |||
GCTCX | 43.19 | -0.93 | -2.11% |
Goldman Sachs US Tax-Managed Eq C |